A Seamless Phase I/II Platform Design with a Time-To-Event Efficacy Endpoint for Potential COVID-19 Therapies

Jaki, Thomas and Barnett, Helen and Titman, Andrew and Mozgunov, Pavel (2024) A Seamless Phase I/II Platform Design with a Time-To-Event Efficacy Endpoint for Potential COVID-19 Therapies. Statistical Methods in Medical Research, 33 (11-12). pp. 2115-2130. ISSN 0962-2802

Text (jaki-et-al-2024-a-seamless-phase-i-ii-platform-design-with-a-time-to-event-efficacy-endpoint-for-potential-covid-19)
jaki-et-al-2024-a-seamless-phase-i-ii-platform-design-with-a-time-to-event-efficacy-endpoint-for-potential-covid-19.pdf - Published Version
Available under License Creative Commons Attribution.
Download (1MB)

Abstract

In the search for effective treatments for COVID-19, initial emphasis has been on re-purposed treatments. To maximise the chances of finding successful treatments, novel treatments that have been developed for this disease in particular, are needed. In this manuscript we describe and evaluate the statistical design of the AGILE platform, an adaptive randomized seamless Phase I/II trial platform that seeks to quickly establish a safe range of doses and investigates treatments for potential efficacy. The bespoke Bayesian design (i) utilizes randomization during dose-finding, (ii) shares control arm information across the platform, and (iii) uses a time-to-event endpoint with a formal testing structure and error control for evaluation of potential efficacy. Both single agent and combination treatments are considered. We find that the design can identify potential treatments that are safe and efficacious reliably with small to moderate sample sizes.